Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The aim of the study was to propose a signature based on genes associated with antigen processing and presentation (APscore) to predict prognosis and response to immune checkpoint inhibitors (ICIs) in advanced gastric cancer (aGC).
Background: How antigen presentation-related genes affected the immunotherapy response and whether they could predict the clinical outcomes of the immune checkpoint inhibitor (ICI) in aGC remain largely unknown.
Methods: In this study, an aGC cohort (Kim cohort, RNAseq, N=45) treated by ICIs, and 467 aGC patients from seven cohorts were conducted to investigate the value of the APscore predicting the prognosis and response to ICIs. Subsequently, the associations of the APscore with the tumor microenvironment (TME), molecular characteristics, clinical features, and somatic mutation variants in aGC were assessed. The area under the receiver operating characteristic curve (AUROC) of the APscore was analyzed to estimate response to ICIs. Cox regression or Log-rank test was used to estimate the prognosis of aGC patients.
Results: The APscore constructed by principal component analysis algorithms was an effective predictive biomarker of the response to ICIs in the Kim cohort and 467 aGC patients (Kim: AUC =0.85, 95% CI: 0.69-1.00; 467 aGC: AUC =0.69, 95% CI: 0.63-0.74). The APscore also was a prognostic biomarker in 467 aGC patients (HR=1.73, 95% CI: 1.21-2.46). Inhibitory immunity, decreased TMB and low stromal scores were observed in the high APscore group, while activation of immunity, increased TMB, and high stromal scores were observed in the low APscore group. Next, we evaluated the value of several central genes in predicting the prognosis and response to ICIs in aGC patients, and verified them using immunogenic, transcriptomic, genomic, and multi-omics methods. Lastly, a predictive model built successfully discriminated patients with vs. without immunotherapy response and predicted the survival of aGC patients.
Conclusions: The APscore was a new biomarker for identifying high-risk aGC patients and patients with responses to ICIs. Exploration of the APscore and hub genes in multi-omics GC data may guide treatment decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615473 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.992060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.
ESMO Open
September 2025
Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain; Clínic Barcelona
Background: Response to trastuzumab combined with chemotherapy (T-chemo) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) varies widely, highlighting the need for more precise biomarkers beyond conventional HER2 assessment with immunohistochemistry (IHC) and in situ hybridization (ISH). The HER2DX ERBB2 messenger RNA (mRNA) assay, a clinically validated genomic test initially developed for early-stage HER2-positive breast cancer, quantitatively measures ERBB2 expression and may improve patient selection for T-chemo in AGC.
Patients And Methods: In a retrospective cohort of 134 patients with AGC, including 58 who received T-chemo, we evaluated whether the HER2DX ERBB2 score defines more accurately HER2 status and correlates with treatment response and survival outcomes in HER2-positive AGC, compared with standard pathology-based methods.
Expertise in Gynecological Pathology Impacts Diagnosis of Atypical Glandular Cell Category in Cervical Cytology.
J Low Genit Tract Dis
August 2025
Department of Pathology, The University of Chicago, Chicago, IL.
Objectives: The Pap test is effective for detecting squamous neoplasia, but the interpretation of atypical glandular cell (AGC) remains challenging because of its rarity, complex cytologic features, and interobserver variability. Although AGC represents a small proportion of Pap test diagnoses, it often leads to extensive follow-up. This study aimed to assess whether gynecologic pathology expertise improves diagnostic accuracy and reduces unnecessary interventions in AGC interpretation.
View Article and Find Full Text PDFComorbidities and comorbidity burden in patients with neurocognitive disorders: findings from the MEMORA Cohort Study.
Eur Geriatr Med
August 2025
Clinical and Research Memory Center of Lyon, Charpennes Hospital, Department of Geriatric Medicine, Lyon Institute For Aging, Hospices Civils de Lyon, Lyon 1 University, 27 rue Gabriel Péri, 69100, Villeurbanne, France.
Aim: This study aimed to compare comorbidities' prevalence and the comorbidity burden as measured by comorbidity indices according to the stages and the etiological diagnoses of neurocognitive disorders (NCD). This study aimed also to examine how comorbidities and comorbidity indices were associated with both stages and etiologies of NCD.
Methods: This is a cross-sectional study including participants from the MEMORA real-life cohort, aged ≥ 60 years.
A nomogram based on plasma HSP90α and NLR for predicting prognosis in advanced gastric cancer patients treated with PD-1 inhibitors.
J Cancer
July 2025
Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
To investigate the use of heat shock protein 90alpha (HSP90α) as a marker for prognostic evaluation and efficacy monitoring in patients receiving PD-1 inhibitors treatment for advanced gastric cancer (AGC). We investigated the value of HSP90α in AGC patients treated with PD-1 inhibitors from a clinical perspective using human plasma samples. In summary, plasma HSP90α was significantly associated with neutrophil-to-lymphocyte (NLR) in AGC patients at baseline.
View Article and Find Full Text PDFArticle Synopsis
- Early gastric cancer (EGC) is a crucial stage to prevent the transition to advanced gastric cancer (AGC), and understanding its single-cell characteristics may enhance monitoring and treatment outcomes.
- A single-cell RNA sequencing atlas was created using 184,426 cancer cells from various stages, revealing eight distinct cell lineages and changes in cell composition as the disease progresses.
- The study identified the role of IL-33 in promoting endothelial cell survival and tumor growth in EGC, highlighting its potential as a predictive marker and therapeutic target.